Peds II (Pediatric Eplerenone Development Study II) - an open label, long-term study to evaluate the safety of eplerenone in the treatment of hypertension in children
Latest Information Update: 24 Dec 2020
Price :
$35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Acronyms PEDS-II
- 29 Aug 2006 Status change
- 30 Oct 2005 New trial record.